INTRODUCTION AND HYPOTHESIS: We evaluated the efficacy of transurethral injection (TUI) for the treatment of recurrent or persistent stress urinary incontinence after mid-urethral sling (MUS) procedures. METHODS: A retrospective study was conducted among 23 women who had undergone TUI for failed MUS using bulking agents, Macroplastique® and Durasphere®. The Sandvik questionnaire, Subjective Symptom Visual Analogue Scale (VAS), Incontinence Quality of Life (I-QOL) assessment, and Benefit, Satisfaction, and Willingness to Continue questionnaire were used to evaluate the efficacy of TUI. RESULTS: The cure rate was 34.8% for a median follow-up of 10 months. Subjective symptom VAS, total, and all domains of I-QOL scores were significantly improved after TUI. Ninety-two percent of the patients reported a benefit and 77% of the patients were satisfied with the treatment. CONCLUSIONS: TUI for failed MUS demonstrated a low cure rate but high patient satisfaction, and the procedure was minimally invasive with no significant complications.
INTRODUCTION AND HYPOTHESIS: We evaluated the efficacy of transurethral injection (TUI) for the treatment of recurrent or persistent stress urinary incontinence after mid-urethral sling (MUS) procedures. METHODS: A retrospective study was conducted among 23 women who had undergone TUI for failed MUS using bulking agents, Macroplastique® and Durasphere®. The Sandvik questionnaire, Subjective Symptom Visual Analogue Scale (VAS), Incontinence Quality of Life (I-QOL) assessment, and Benefit, Satisfaction, and Willingness to Continue questionnaire were used to evaluate the efficacy of TUI. RESULTS: The cure rate was 34.8% for a median follow-up of 10 months. Subjective symptom VAS, total, and all domains of I-QOL scores were significantly improved after TUI. Ninety-two percent of the patients reported a benefit and 77% of the patients were satisfied with the treatment. CONCLUSIONS: TUI for failed MUS demonstrated a low cure rate but high patient satisfaction, and the procedure was minimally invasive with no significant complications.
Authors: Christopher F Maher; Barry A O'Reilly; Peter L Dwyer; Marcus P Carey; Anne Cornish; Philip Schluter Journal: BJOG Date: 2005-06 Impact factor: 6.531
Authors: Evangelia Bakali; Eugenie Johnson; Brian S Buckley; Paul Hilton; Ben Walker; Douglas G Tincello Journal: Cochrane Database Syst Rev Date: 2019-09-04
Authors: Jerry G Blaivas; Rajveer S Purohit; Matthew S Benedon; Gabriel Mekel; Michael Stern; Mubashir Billah; Kola Olugbade; Robert Bendavid; Vladimir Iakovlev Journal: Nat Rev Urol Date: 2015-08-18 Impact factor: 14.432